BrainsWay Ltd. (BWAY) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$12.05

From 52W high−30.17%

Volume108834.00

Market cap$482.63M

P/E (TTM)26.1x

P/S (TTM)7.9x

Div yield—

Key dataOct 19, 2026

Open

$12.05

From 52W high

−30.17%

Volume

108834.00

Market cap

$482.63M

ValuationView details →

P/E (Fwd)

26.4x

EV/EBITDA

35.1x

P/E (TTM)

26.1x

RSI (14)

43.5

MomentumView details →

1D Return

+4.81%

YTD Return

+27.13%

SummaryUpdated Jun 1, 2026

BrainsWay Ltd. (NASDAQ:BWAY) is an Israeli medical device company founded in 2003 and headquartered in Jerusalem. The company went public on NASDAQ in April 2019. BrainsWay develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS) technology, a non-invasive neurostimulation treatment platform for various mental health and neurological disorders. The company has evolved from a research-focused startup to a profitable medical device manufacturer with over 1,350 systems installed globally and a growing presence in both domestic U.S. and international markets.

Ask drillr about BrainsWay Ltd. →

ValuationView details →

P/E (Fwd)

26.4x

P/E (TTM)

26.1x

EV/EBITDA

35.1x

EV/Sales

7.0x

P/S (TTM)

7.9x

P/B (TTM)

6.1x

ProfitabilityView details →

Gross Margin

75.32%

Net Margin

15.65%

EBITDA Margin

19.98%

ROE (TTM)

12.05%

ROA (TTM)

7.83%

Asset Turnover

0.51x

GrowthView details →

Revenue YoY

+32.34%

EPS YoY

+185.36%

FCF YoY

−69.62%

Revenue CAGR 3Y

+24.33%

EPS CAGR 3Y

+365.12%

EBITDA YoY

+43.99%

MomentumView details →

1D Return

+4.81%

YTD Return

+27.13%

1Y Return

+52.27%

RSI (14)

43.5

vs 50D SMA

−12.05%

vs 200D SMA

−13.53%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

3.59x

Quick Ratio

3.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.14

EPS Surprise

40.00%

Beats (12Q)

6/12

Next Q EPS Est

$0.09

Avg Surprise (4Q)

147.43%

Rev Surprise

3.42%

Financials snapshotView financials →

Revenue (TTM)

60.99M

Net Income (TTM)

9.55M

Op. CF (TTM)

8.16M

Next earningsNov 10, 2026 →

Latest newsMore news →

Brainsway Ltd. announced a strategic collaboration with Inland Psychiatry Medical Group to accelerate the application of interventional psychiatry treatments.11h ago

BrainsWay announced that favorable U.S. medical-policy coverage for its SWIFT Accelerated Deep TMS protocol had expanded to cover more than 70 million lives.6d ago

Similar companies

SS Innovations International, Inc.SSII Venus Medtech (Hangzhou) Inc.02500.HK 908 Devices Inc.MASS Vincent Medical Holdings Limited01612.HK Delcath Systems, Inc.DCTH Sight Sciences, Inc.SGHT Find similar companies →

Latest newsMore news →

Brainsway Ltd. announced a strategic collaboration with Inland Psychiatry Medical Group to accelerate the application of interventional psychiatry treatments.11h ago BrainsWay announced that favorable U.S. medical-policy coverage for its SWIFT Accelerated Deep TMS protocol had expanded to cover more than 70 million lives.6d ago